Applied DNA SciencesAPDN
APDN
About: Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
Employees: 48
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
43% more funds holding
Funds holding: 21 [Q3] → 30 (+9) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
4.87% less ownership
Funds ownership: 7.38% [Q3] → 2.51% (-4.87%) [Q4]
84% less capital invested
Capital invested by funds: $1.64M [Q3] → $267K (-$1.38M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for APDN.
Financial journalist opinion
Based on 3 articles about APDN published over the past 30 days
Neutral
Accesswire
1 day ago
Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
- Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases - STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), its wholly-owned clinical laboratory subsidiary, is repositioning its TR8™ PGx pharmacogenomics testing service to offer tailored subpanels for indication-specific use cases in addition to full panel testing. The first subpanel under ADCL's new go-to-market strategy is for the pre-emptive testing of patients with genetic variants of the DPYD gene that correlate to potentially reduced or absent DPD enzyme activity necessary to metabolize fluoropyrimidines, specifically capecitabine (branded Xeloda) and fluorouracil (5-FU), two chemotherapy drugs that are widely used as part of the standard of care treatment for patients with certain cancers.
Neutral
Accesswire
1 week ago
Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test
STONY BROOK, NY / ACCESS Newswire / March 26, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), the Company's wholly-owned clinical laboratory subsidiary, has submitted a validation package to the New York State Department of Health (NYSDOH) to request approval as a laboratory-developed test (LDT) for a PCR-based assay for the detection and subtyping of influenza A (H5) virus, also known as H5 bird flu, highly pathogenic avian influenza, or H5N1 (collectively "H5 bird flu"). ADCL's Linea™ Avian Influenza H5 Dx assay ("AIH5 Dx") is a highly sensitive, multi-target diagnostic assay capable of detecting and discriminating between pan-influenza A and H5 bird flu.
Neutral
Accesswire
3 weeks ago
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
STONY BROOK, NY / ACCESS Newswire / March 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-50 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m.
Neutral
Seeking Alpha
1 month ago
Applied DNA Sciences, Inc. (APDN) Q1 2025 Earnings Call Transcript
Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q1 2025 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sanjay Hurry - Executive Director, IR & Corporate Communications Beth Jantzen - CFO James Hayward - Chairman & CEO Clay Shorrock - Chief Legal Officer & Executive Director, Business Development Judith Murrah - President & Secretary Conference Call Participants Eduardo Arce - H.C. Wainwright & Co Operator Good day, and welcome to the Applied DNA Sciences First Quarter Fiscal 2025 Financial Results.
Negative
Zacks Investment Research
1 month ago
Applied DNA Sciences (APDN) Reports Q1 Loss, Tops Revenue Estimates
Applied DNA Sciences (APDN) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.80 per share a year ago.
Neutral
Accesswire
1 month ago
Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
- Announces Exit of DNA Tagging and Security Products and Services Business Segment - - Workforce Reduction of 20% of Headcount Implemented in January - - GMP Site 1 Facility Complete and Certified for Commercial Operation in January - - Webcast and Conference Call Scheduled for today at 4:30 PM ET - STONY BROOK, NY / ACCESS Newswire / February 13, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today reported financial results for its first quarter of fiscal 2025 ended December 31, 2024. The Company's Form 10-Q, once filed, can be viewed on the SEC Filings page of its Investor Relations website.
Neutral
Accesswire
1 month ago
Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
Investor Call and Webcast Scheduled for 4:30 P.M ET STONY BROOK, NY / ACCESS Newswire / February 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2025 financial results after the market close on Thursday, February 13, 2025. The Company will host a conference call for shareholders and the investment community at 4:30 p.m.
Neutral
Accesswire
1 month ago
Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14
STONY BROOK, NY / ACCESS Newswire / February 11, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today issued a reminder to its shareholders to vote ahead of a reconvening of a Special Meeting of Stockholders (the "Special Meeting") to be held on Friday, February 14, 2025 at 11:00 a.m. The Company's Board of Directors encourages any shareholder as of the record date of November 25, 2024, who has not yet voted their shares on the Warrant Exercise Proposal (as defined below), to contact Kingsdale Advisors to vote their shares: 1-855-682-9644 or by e-mail at contactus@kingsdaleadvisors.com.
Neutral
Accesswire
2 months ago
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
- Signals Start of New Commercialization Phase for LineaRx Subsidiary - - Company Negotiating GMP Supply Agreement - - Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing final testing and is expected to be fully operational by the end of the current month.
Neutral
Accesswire
2 months ago
Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results. The Company originally scheduled an Investor Update call for January 9, 2025, to update shareholders on its strategic restructuring announced in December 2024 and GMP initiative.
Charts implemented using Lightweight Charts™